The Japan Pharmaceutical Manufacturers Association (JPMA) is a voluntary association comprising 73 research-oriented pharmaceutical companies (as of July, 2021).
JPMA, celebrating its 50th anniversary in 2018, has been contributing to advancing global healthcare through the development of innovative ethical drugs, facilitating sound development of the pharmaceutical industry through proactively establishing policies and recommendations in response to globalization and enhancing public understanding of pharmaceuticals.
As a member of the IFPMA (International Federation of Pharmaceutical Manufacturers & Associations), JPMA is engaged with various global issues in the pharmaceutical and healthcare sector, including countermeasures against emerging diseases across the globe and infectious diseases in developing countries, drug access problems, intellectual property rights and the threat of counterfeit drugs.
Working collaboratively with PhRMA (Pharmaceutical Research and Manufacturers of America) and EFPIA (European Federation of Pharmaceutical Industries and Associations), JPMA takes active roles at ICH (International Conference on Harmonization), which aims at international harmonization of pharmaceutical regulations.
Through mutual information sharing and close collaboration with each member organization, JPMA continues to act globally for the advancement of medical treatments for patients worldwide.